MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical On
– Zandelisib Demonstrated 70.3% Objective Response Rate and 35.2% Complete Response Rate –– 87.5% of Responses Achieved in First Two Cycles of Therapy, 75% of CRs in First Four Cycles –– 9.9% of Patients Discontinued Therapy Due to a Drug Related Adverse Event –– 83% Reported Grade 3 Adverse Events of Special Intere...
United States Richard Ghalie Asia Pacific Andrew David Zelenetz Davida Walsey American Society Of Clinical Oncology
Source: pharmiweb.com